Tag: M.W=150-200

Abu Zuhri, Ali Z. published the artcilePolarography of pyridine-2-carboxaldehyde 2-pyridylhydrazone in solutions of varying pH at a dropping-mercury electrode: effect of surface-active substance, Safety of 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, the publication is Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1985), 499-502, database is CAplus.

The polarog. behavior of pyridine-2-carboxaldehyde 2-pyridylhydrazone (I) at a dropping-Hg electrode was studied in aqueous Britton-Robinson buffers containing 50% EtOH. The polarograms consist of one wave in the acidic and alk. medium. Two electrons are consumed in the splitting of the N-N bond to give 2-aminopyridine and pyridine-2-carboxaldehyde. The adsorption effects of cationic, anionic, and nonionic surfactants on the polarog. waves of I were investigated. The kinetic parameters for the electrode reaction at different pH values were calculated

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) published new progress about 2215-33-0. 2215-33-0 belongs to pyridine-derivatives, auxiliary class Pyridine,Amine, name is 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, and the molecular formula is C11H10N4, Safety of 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Arora, Bhavya published the artcileFabrication of a recyclable magnetic halloysite-based cobalt nanocatalyst for the efficient degradation of bisphenol A and malachite green, Quality Control of 91-02-1, the publication is Materials Advances (2022), 3(15), 6373-6384, database is CAplus.

Worsening water quality has drawn considerable attention from the scientific fraternity owing to its serious impact on human health and environmental ecosystem. In this regard, magnetic halloysite-based organic-inorganic hybrid materials with a hollow nanotubular structure and surface tunable chem. have emerged as an excellent platform for the efficient removal of recalcitrant water contaminants. The fabrication of nanocatalyst involves a simple yet versatile covalent immobilization strategy, wherein a chelating ligand, 2-benzoylpyridine (2-BPy) was grafted onto silane-functionalized magnetic halloysite nanotubes with subsequent anchoring of cobalt ions. Various physico-chem. techniques such as FT-IR spectroscopy, P-XRD, VSM, FE-SEM, TEM and XPS provided valuable insights into the crystallinity, magnetic attributes and morphol. of the designed nanocomposites. The exptl. results indicated that a Co(II)@2-BPy@APTES@MHNTs/H₂O₂ catalytic system not only exhibits immense catalytic potential in accelerating the degradation process but also shows impressive features such as shorter reaction time and ambient reaction conditions. With the assistance of coumarin fluorescent probe technique and radical scavenging studies, the mechanistic pathway has been proposed, and it has been found that in situ generated highly reactive hydroxyl radicals play a crucial role in achieving outstanding degradation efficiency. The kinetic characteristics of the degradation profile demonstrate that pseudo-first-order kinetics is followed with an apparent rate constant of 0.1179 min^-1 for BPA and 0.1242 min^-1for MG. Fascinatingly, the splendid magnetic properties of the designed Co(II)@2-BPy@APTES@MHNTs furnished their facile recovery and reusability for nine subsequent runs. Remarkably, the new findings demonstrated here will deepen our understanding of the fabrication and utilization of heterogeneous catalysts for wastewater treatment via a greener approach.

Materials Advances published new progress about 91-02-1. 91-02-1 belongs to pyridine-derivatives, auxiliary class Pyridine,Benzene,Ketone, name is Phenyl(pyridin-2-yl)methanone, and the molecular formula is C12H9NO, Quality Control of 91-02-1.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Chatterjea, J. N. published the artcileSynthesis in the 4-azafluorene group. Part III, Safety of 1-(Cyanomethyl)pyridin-1-ium chloride, the publication is Journal of the Indian Chemical Society (1978), 55(2), 149-53, database is CAplus.

Cyclocondensation of benzylideneindandiones I (R = H, Me, MeO, NO₂) with NH₄OAc in the presence of 1-phenacylpyridinium bromide gave the diindenopyridines II. Hantzsch cyclization of 2-benzylidene-1-indanone with PhC(NH₂):CCN gave the dihydroazafluorenone III, which was aromatized by chromic acid, hydrolyzed, and decarboxylated to give the azafluorenone IV (Z = O). Wolff-Kishner reduction of IV (Z = O) gave IV (Z = H₂). Treatment of 2-benzylideneindan-1-one with NH₄OAc and 1-acetonylpyridinium bromide gave 3-methyl-1-phenyl-4-azafluorene, which was also obtained from Et 3-methyl-1-phenyl-4-azafluorenone-2-carboxylate by successive hydrolysis, decarboxylation, and Wolff-Kishner reduction 1-Benzylidene-2-indanone was prepared from Et 3-benzylidene-2-oxo-1-indancarboxylate by hydrolysis-decarboxylation.

Journal of the Indian Chemical Society published new progress about 17281-59-3. 17281-59-3 belongs to pyridine-derivatives, auxiliary class Pyridine,Nitrile,Salt, name is 1-(Cyanomethyl)pyridin-1-ium chloride, and the molecular formula is C7H7ClN2, Safety of 1-(Cyanomethyl)pyridin-1-ium chloride.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Pellerano, C. published the artcileTridentate N-N-N chelating systems as potential antitumoral agents, Computed Properties of 2215-33-0, the publication is Farmaco, Edizione Scientifica (1985), 40(9), 645-54, database is CAplus and MEDLINE.

Tridentate chelating agents were prepared as derivatives of 2-quinolylhydrazine (I; R = H, Me; R¹ = H, Me, MeO; R² = H, Me; R³ = H, Me), 2-pyridylhydrazine (II; R² = H, Me, Ph; R³ = H, Me), and 2-benzothiazolylhydrazine (III; R² = H, Me, Ph; R³ = H, Me) and tested for antitumor activity in mice bearing lymphocytic leukemia P388. Several of the compounds, including 1-(4‘-methyl-2‘-quinolyl)-3-(2‘-pyridyl)-1,2-diaza-2-propene  [71508-71-9], showed some activity against lymphocytic leukemia P388 in mice; the latter compound, however, was inactive when tested against other tumors.

Farmaco, Edizione Scientifica published new progress about 2215-33-0. 2215-33-0 belongs to pyridine-derivatives, auxiliary class Pyridine,Amine, name is 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, and the molecular formula is C11H10N4, Computed Properties of 2215-33-0.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Pellerano, C. published the artcileQuinolylhydrazones of acetylpyridines: synthesis and biological activity. Part VII, Quality Control of 2215-33-0, the publication is Bollettino Chimico Farmaceutico (1978), 117(12), 721-30, database is CAplus and MEDLINE.

The condensation of acetylpyridine isomers with hydrazinoquinoline isomers yielded hydrazones I (R = H, Me, OMe, Cl; R¹ = H, Me), which exhibited bactericidal and tuberculostatic activity.

Bollettino Chimico Farmaceutico published new progress about 2215-33-0. 2215-33-0 belongs to pyridine-derivatives, auxiliary class Pyridine,Amine, name is 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, and the molecular formula is C11H10N4, Quality Control of 2215-33-0.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Seydel, Joachim Karl published the artcileDevelopment of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the Mycobacterium avium complex, Computed Properties of 2215-33-0, the publication is Chemotherapy (Basel, Switzerland) (1992), 38(3), 159-68, database is CAplus and MEDLINE.

Rationally designed combinations of rifampicin (RAMP) and thiacetazone plus isonicotinic acid hydrazide and/or ethambutol are highly effective in the treatment of patients (including HIV-pos.) infected with multiply resistant mycobacteria of the M. avium complex (MAC). Clin. results are very promising. The high efficacy of these combinations is due to the synergistic potentiation of single-drug activities. As soon as rifabutin is marketed, it should replace RAMP in the combination treatment of patients with highly RAMP-resistant MAC bacteria.

Chemotherapy (Basel, Switzerland) published new progress about 2215-33-0. 2215-33-0 belongs to pyridine-derivatives, auxiliary class Pyridine,Amine, name is 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, and the molecular formula is 0, Computed Properties of 2215-33-0.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Bobbio, Carla published the artcileSelective Functionalization of 2-Fluoropyridine, 2,3-Difluoropyridine, and 2,5-Difluoropyridine at Each Vacant Position, Computed Properties of 851386-45-3, the publication is Journal of Organic Chemistry (2005), 70(8), 3039-3045, database is CAplus and MEDLINE.

The concept of “regioexhaustive substitution” has been successfully applied to 2-fluoro-, 2,3-difluoro-, and 2,5-difluoropyridine. All vacant positions were amenable to regioselective metalation and subsequent carboxylation by employing either chlorine as a neighboring site activating protective group or trimethylsilyl as a neighboring site screening protective group. In this way, approx. half a dozen fluorinated pyridinecarboxylic acids were derived from each starting material.

Journal of Organic Chemistry published new progress about 851386-45-3. 851386-45-3 belongs to pyridine-derivatives, auxiliary class Pyridine,Fluoride,Carboxylic acid, name is 3,6-Difluoropicolinic acid, and the molecular formula is C6H3F2NO2, Computed Properties of 851386-45-3.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Essery, J. M. published the artcileDerivatives of 4-amino- and 4-nitropyridine, HPLC of Formula: 102236-19-1, the publication is Journal of the Chemical Society (1960), 4953-9, database is CAplus.

The following were prepared by conventional procedures. A series of substituted pyridine 1-oxides (substituent given): 3-Et (I), hygroscopic oil, b₁₂ 123-5°, picrate, m. 95°; 3-iso-Pr, b_0.8 120-2°, picrate, m. 125-6°; 3-tert-Bu (Ia), b₁ 132-4°, picrate, m. 143-4°; 3,5-Me₂, b_0.1 116-18°, picrate, m. 135-6°; 2,3,5,6-Me₄, needles, m. 139-40°, picrate, m. 144-5°; and 3-Br, -, picrate, m. 144.5-5.5°. I (24.5 g.), 65 ml. concentrated H₂SO₄ and 34 ml. concentrated HNO₃ were warmed to 50° to initiate reaction, then heated 3.5 hrs. at 90-100°, the whole cooled, neutralized with solid K₂CO₃, filtered, the filtrate extracted with CHCl₃ and the CHCl₃ concentrated gave 19 g. 3-ethyl-4-nitropyridine 1-oxide (II), yellow needles, m. 68-9°. In similar fashion were prepared the following substd. 4-nitropyridine 1-oxides: 3-iso-Pr, m. 138-9°; 3,5-Me₂ (IIa), m. 174-5° (picrate m. 137.5-8.5°); 2,3, 5,6-Me₄ (IIb), m. 115-16° (picrate m. 160-1°); 3-Br, m. 156-7° [small amount of 3,4-Br(O₂N)C₅H₃N also formed]. 3-tert-Butyl-2(or 6-)nitropyridine (IIc) m. 104.5-5.5°. To 5 g. II in 100 ml. dry CHCl₃ at 0-10° was added 25 ml. PCl₃, the whole kept 0.67 hr. at 10° poured on ice, treated with excess NaOH, extracted with CHCl₃, and the CHCl₃ extracts concentrated to give 3.8 g. 3,4-Et(O₂N)C₅H₃N, b_0.25 56-8°. Similarly were prepared 3,4-iso-Pr(O₂N)C₅H₃N, b_0.85 82-4° (picrate m. 106-7°); 3,5,4-Me₂(O₂N)C₅H₂N.0.5.H₂O, m. 38-9° (picrate m. 169-70°); and 2,3,5,6,4-Me₄(O₂N)C₅N.2H₂O, m. 198-200° (picrate m. 174-6°). To 13 g. II was added 60 ml. AcCl; a vigorous reaction occurred. Subsequently, the mixture was poured on ice, the whole treated with excess NaOH and the product isolated via CHCl₃ extraction to give 8.2 g. 4-chloro-3-ethylpyridine 1-oxide (IId), m. 86° (picrate m. 137-8°). The following substituted 4-chloropyridine 1-oxides were similarly prepared: 3-iso-Pr, hygroscopic, m. 87-8° (picrate m. 130-1°); 3,5-Me₂ (III), m. 201-2° (picrate m. 142-3°); 2,3,5,6-Me₄, m. 153-4° (picrate m. 154-5°); 3-Br, m. 153.5-4.5° (picrate m. 120-1°). III (2.5 g.) and 18 ml. concentrated aqueous NH₃ heated 18 hrs. at 140°, the whole cooled, treated with 2.5 g. K₂CO₃, evaporated to dryness and the residue extracted with AcEt gave 1.6 g. 4-amino-3,5-dimethylpyridine 1-oxide-2H₂O (IV), m. 227-9°, picrate m. 221-3°. 3,4-Me(O₂N)C₅H₃N (2.5 g.), 50 ml. EtOH, 4 ml. 90% H₂NNH₂.H₂O, and a small amount of Raney Ni (V) were heated 0.5 hr. on the steam bath, more V added, the whole filtered, and the filtrate concentrated to give 1.2 g. 3,4-Me(H₂N)C₅H₃N, m. 108-9°. This procedure also gave 3,4-Et(H₂N)C₅H₃N.0.5.H₂O, m. 52-3° (picrate m. 196-7°); 3,4-iso-Pr(H₂N)C₅H₃N.0.5.H₂O, m. 69-70° (picrate m. 156-7°). To 0.5 g. IV in 5 ml. AcOH was added 0.3 g. Fe dust, the whole heated 1.5 hrs. on the steam bath, cooled, treated with excess NaOH and the product isolated via Et₂O extraction to give 0.2 g. 3,5,4-Me₂(H₂N)C₅H₂N.2H₂O (VI), m. 83-4° (picrate m. 226-7°). Alternately, 2 g. IIa, 25 ml. MeOH, 2 g. Raney Ni, and H gave 1.1 g. VI; the same procedure with IIb gave the amino derivative hemihydrate m. 196-7° (picrate m. 225-6°). Both reduction procedures with IIc gave the amino derivatives, m. 128-9°, λ 292, 228 mμ (log ε 3.56, 4.9) (picrate m. 242°). IId (3 g.) and 18 ml. 30% aqueous MeNH₂ heated 18 hrs. at 140° gave, as above with IV, 2.1 g. 3-methyl-4-methylaminopyridine 1-oxide (VII), m. 106-7° (picrate m. 184-5°). Similarly were prepared the following substituted 4-methylaminopyridine 1-oxides: 3-Et, b_0.5 120-2°, m. 117-18° (picrate m. 182-3°); 3-iso-Pr (VIII) (no m.p. given) (picrate m. 164-5°); 3,5-Me₂, m. 94.5-5.5° (picrate m. 172-3°); 3-Br, hygroscopic solid (picrate m. 189-91°) and 2,3,5,6-Me₄, hygroscopic solid (picrate m. 140-1°). VII reduced by Fe in AcOH gave 3,4-Me(MeNH)C₅H₃N, m. 125-6° (picrate m. 199-200°). VIII hydrogenated as above gave 3,3-iso-Pr-(MeNH)C₅H₃N, m. 95-6° (picrate m. 159-60°) and this procedure gave the following 3-substituted 4-(MeNH)C₅H₃N derivatives): 3,5-Me₂, m. 119.5-20.5° (picrate m. 194.5-5.5°); 2,3,5,6-Me₄, m. 118-19° (picrate m. 160-1°); 3-Br, 92-3°. The following were prepared by the above procedures: 3,4-Me(Me₂N)C₅H₃N (IX), b₁ 73-5° (picrate m. 172-3°) and IX 1-oxide, b_0.15 142-4° (picrate m. 130-1°); 3,4-Et(Me₂N)C₅H₃N (X), b_0.6 82-3° (picrate m. 118-19°) and X 1-oxide, b₁ 178-80° (picrate m. 139-40°); 3,4-iso-Pr-(Me₂N)C₅H₃N (XI), b_0.45 79-80° (picrate m. 138-9°) and XI 1-oxide, – (picrate m. 151-2°); 3,5,4-Me₂(Me₂N)C₅H₂N (XII), b_0.4 69-7° (picrate m. 172-3°) and XII 1-oxide m. 83-4° (picrate m. 115-16°); and 3,4-Br(Me₂N)C₅H₃N (XIII), b_0.5 82-4° (picrate m. 182-3°) and XIII 1-oxide, – (picrate m. 160-1°). Ia (3.5 g.) and SO₂Cl₂ heated 2 hrs. at 110-20° gave 2 products, C₉H₁₂ClN, giving picrates, m. 152-3° and 149-50°.

Journal of the Chemical Society published new progress about 102236-19-1. 102236-19-1 belongs to pyridine-derivatives, auxiliary class Pyridine,Chloride, name is 5-(tert-Butyl)-2-chloropyridine, and the molecular formula is C9H12ClN, HPLC of Formula: 102236-19-1.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Luecking, Ulrich published the artcileIdentification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer, Formula: C6H8BNO3, the publication is ChemMedChem (2017), 12(21), 1776-1793, database is CAplus and MEDLINE.

Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy. Starting from lead compound BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochem. and DMPK properties finally led to the identification of the orally available clin. candidate atuveciclib (BAY 1143572). Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats. BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clin. trials for the treatment of cancer.

ChemMedChem published new progress about 1008506-24-8. 1008506-24-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Ether,Pyridine,Boronic Acids,Boronic acid and ester, name is 3-Methoxypyridine-4-boronic acid, and the molecular formula is C6H8BNO3, Formula: C6H8BNO3.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Mueller, Sebastian L. published the artcileSystematic variation of the benzenesulfonamide part of the GluN2A selective NMDA receptor antagonist TCN-201, COA of Formula: C5H5NO3S, the publication is European Journal of Medicinal Chemistry (2017), 124-134, database is CAplus and MEDLINE.

GluN2A subunit containing N-methyl-D-aspartate receptors (NMDARs) are highly involved in various physiol. processes in the central nervous system, but also in some diseases, such as anxiety, depression and schizophrenia. However, the role of GluN2A subunit containing NMDARs in pathol. processes is not exactly elucidated. In order to obtain potent and selective inhibitors of GluN2A subunit containing NMDARs, the selective neg. allosteric modulator 2 was systematically modified at the benzenesulfonamide part. The activity of the test compounds was recorded in two electrode voltage clamp experiments using Xenopus laevis oocytes expressing exclusively NMDARs with GluN1a and GluN2A subunits. It was found that halogen atoms in 3-position of the benzenesulfonamide part result in high GluN2A antagonistic activity. With an IC₅₀ value of 204 nM the 3-bromo derivative 5i (N-{4-[(2-benzoylhydrazino)carbonyl]benzyl}-3-bromobenzenesulfonamide) has 2.5-fold higher antagonistic activity than the lead compound 2 and represents our new lead compound

European Journal of Medicinal Chemistry published new progress about 636-73-7. 636-73-7 belongs to pyridine-derivatives, auxiliary class Pyridine,Sulfonic acid, name is Pyridine-3-sulfonic acid, and the molecular formula is C5H5NO3S, COA of Formula: C5H5NO3S.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem